BO 2502A

Drug Profile

BO 2502A

Alternative Names: BO 2502B

Latest Information Update: 19 Feb 2008

Price : $50

At a glance

  • Originator Banyu
  • Class Antibacterials; Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 05 Apr 2001 No-Development-Reported for Bacterial infections in Japan (unspecified route)
  • 10 Sep 1997 An animal study has been added to the pharmacokinetics and Bacterial infections pharmacodynamics sections
  • 10 Sep 1997 Preclinical development for Bacterial infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top